ABBVIE, INC. for ABBVIE INC.

Taxation/Internal Revenue Code TAX

Senate and House Committee Tax Reform Proposals Puerto Rican Economy and Debt Relief Proposals Proposals to reform domestic and international tax structures

Contacted: Commerce, Dept of (DOC); U.S. Trade Representative (USTR); State, Dept of (DOS); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Health Resources & Services Administration (HRSA)

Trade (domestic/foreign) TRD

U.S. Trade policy, including IP and pharmaceutical market access issues Japan Pricing and Regulatory Issues U.S. IP policy at multilateral organizations Philippine Potential Compulsory Licensing Issue

Contacted: Medicare Payment Advisory Commission (MedPAC); Health Resources & Services Administration (HRSA); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); SENATE; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC)

Health Issues HCR

S. 64: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 92: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 204: Trickett Wendler Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness S. 456: RACE for Children Act - Provisions related to pediatric studies S. 469: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 771: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing H.R. 749: Lower Drug Costs Through Competition Act - Provisions related to generic drug approvals and priority review vouchers H.R. 820: Childhood Cancer STAR Act - Provisions related to expanded access and other policy issues H.R. 878: Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 1231: RACE for Children Act - Provisions related to pediatric studies H.R. 1245: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation H.R. 1628: American Health Care Act of 2017 - Provisions related to the biopharmaceutical industry including repeal of brand pharmaceutical manufacturer fee and individual and employer mandates, insurance affordability provisions, and Medicaid reforms H.R. 1776: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization 340B drug discount program policy issues Orphan Drug Act policy issues Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues H.R. 2430: FDA Reauthorization Act of 2017 - Provisions related to user fee programs

Contacted: Patent & Trademark Office (PTO); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1480 (115th), S. 456 (115th), H.R. 1776 (115th), H.R. 1231 (115th), S. 92 (115th), H.R. 1628 (115th), S. 204 (115th), S. 64 (115th), H.R. 878 (115th), H.R. 2430 (115th), H.R. 1245 (115th), S. 771 (115th), H.R. 749 (115th), S. 469 (115th), H.R. 820 (115th)

Medicare/Medicaid MMM

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal Part D policy issues including non-interference and rebates policy issues Drug cost and pricing policy issues Center for Medicare and Medicaid Innovation (CMMI) transparency and other policy issues

Contacted: U.S. Trade Representative (USTR); Medicare Payment Advisory Commission (MedPAC); SENATE; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Commerce, Dept of (DOC)

Bills named: H.R. 242 (115th), S. 251 (115th), S. 41 (115th), S. 260 (115th), H.J.Res. 51 (115th), H.R. 849 (115th), S.J.Res. 16 (115th)

Copyright/Patent/Trademark CPT

S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues S. 1390: STRONGER Patents Act - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms

Contacted: Patent & Trademark Office (PTO); Commerce, Dept of (DOC); SENATE; Medicare Payment Advisory Commission (MedPAC); Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1390 (115th), S. 124 (115th)

Budget/Appropriations BUD

S.Con.Res 3: Budget Resolution - Provisions related to the biopharmaceutical industry including importation and non-interference H.R. 244: Consolidated Appropriations Act, 2017 H.R. __: Making appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies programs for the fiscal year ending September 30, 2018, and for other purposes Budget of the United States Government, Fiscal Year 2018 - A New Foundation for American Greatness - Provisions related to non-defense program funding including FDA and NIH and repeal of the Independent Payment Advisory Board (IPAB)

Contacted: Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Health Resources & Services Administration (HRSA); Commerce, Dept of (DOC); SENATE

Bills named: H.R. 244 (115th), S.Con.Res. 3 (115th)